comparemela.com

Latest Breaking News On - Luye life sciences - Page 1 : comparemela.com

Overcome hurdles in scaling up mRNA-based therapeutics

Korean, Chinese business leaders to cooperate on stabilizing parts, materials supply chain

PE Digest: Templewater close to buying Luye units; Hillhouse raising Asia private credit fund

Luye Life Sciences Unveils Cutting-edge Advances in Gene and Cell Therapy at ASGCT 2021

Share this article Share this article BOSTON, May 13, 2021 /PRNewswire/ The Boston R&D Center and GeneLeap Biotech, two subsidiaries of Luye Life Sciences Group, took part in the 24 th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, presenting the progress of four of the company s latest preclinical developments in gene and cell therapy to the global biological community. ASGCT is one of the world s most influential academic conferences in the area of gene and cell therapy. More than 3,500 scholars, clinical investigators, physicians and other professionals attend the meeting every year. The ASCCT annual meeting is held as a virtual event from May 11 to 14 this year.

GeneLeap Announces Novel GalNAc Synthesis and Evaluation in Mice as Antisense Oligonucleotide Conjugates at ACS 2021

GeneLeap Announces Novel GalNAc Synthesis and Evaluation in Mice as Antisense Oligonucleotide Conjugates at ACS 2021 News provided by Share this article Share this article BOSTON, April 25, 2021 /PRNewswire/ GeneLeap Biotech, a subsidiary of Luye Life Sciences specializing in the development of nucleic acid therapeutics, presented an e-poster entitled Design and synthesis of novel GalNAc linker moieties, conjugation to antisense oligonucleotides and evaluation in mice at the Spring Meeting of the American Chemical Society (ACS) 2021. The study reported new synthetic methodologies for the synthesis of novel tri-antennary GalNAc units and their evaluation for delivery and efficacy as GalNAc-antisense oligo conjugates in mice.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.